Abstract:Background: Liver cancer is the deadliest malignancy among common tumors. It is the top cause of cancer-related deaths in Egypt, and it is characterized by increasing occurrence among the population. The objective of this study was to determine the outcome of pre-treatment of IQGAP1-shRNA on induced mouse hepatocellular carcinoma model and evaluate the potency of this IQGAP1-shRNA plasmid to recover hepatic cancer as a new tool of cancer therapy. Therefore, we will use RNA interference (RNAi) technology to silence IQGAP1 oncogene to completely recover the chemically induced models for hepatic cancer by designing short RNAi specific for IQGAP1 gene in HCC cells in vivo and construct new vectors suitable for this purpose. We assigned mice into three groups: the first negative control group (NC) was injected with saline, the second control group was injected with shRNA (shNC), the third positive control group was injected with diethylnitrosamine (DENAA), and the fourth group was treated with the IQGAP1-shRNA prior to its exposure to DENA. Results: Our results revealed that the treated group with IQGAP1-shRNA with DENA developed very few cases of hepatic cancer when compared with the positive control group. The positive control group exhibited significant increases in the liver function level as well as a decrease in serum albumin levels when compared to both the treated and the negative control groups. The altered levels of the serum α-fetoprotein as well as of the tumor necrosis factor-alpha, and interleukin-4 in DENA-treated mice were significantly ameliorated by IQGAP1-shRNA administration. Flow cytometer analyses have indicated that the silencing of IQGAP1 cannot significantly modulate DENA-induced apoptosis in the circulating blood cells. Moreover, the elevated mRNA expression levels of IQGAP1, IQGAP3, KRas, HRas, interleukin-8, nuclear factor kappa B, caspase-3, caspase-9 and Bcl-2, were significantly decreased by the IQGAP1-shRNA treatment. However, the IQGAP2, DR4, DR5, p53 and BAX genes were found to be significantly up-regulated post-therapy. In agreement with these findings, IQGAP1-shRNA was able to modulate the DENA-induced histological changes in the mice liver which were represented by severe necrosis and hydropic degenerative changes. Conclusion: Our study revealed that IQGAP1-shRNA was able to preserve hepatocyte integrity and the liver histological architecture through the regulation of the expression of IQGAPs, Ras, TRAILs and IL-8 receptors, as well as of pro-apoptotic and anti-apoptotic genes. Therefore, the silencing of IQGAP1 could be part of a promising therapeutic strategy against hepatic cancer.

Thymoquinone Suppresses Angiogenesis in DEN-Induced Hepatocellular Carcinoma by Targeting miR-1-3p

TQ inhibits hepatocellular carcinoma growth in vitro and in vivo via repression of Notch signaling

Thymoquinone Inhibits Angiogenesis And Prostate Tumor Growth By Suppressing Mapk Signaling Pathways

Thymoquinone Selectively Induces Hepatocellular Carcinoma Cell Apoptosis in Synergism with Clinical Therapeutics and Dependence of P53 Status.

Thymoquinone Suppresses the Proliferation, Migration and Invasiveness through Regulating ROS, Autophagic Flux and miR-877-5p in Human Bladder Carcinoma Cells.

Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways.

Thymoquinone Inhibits the Metastasis of Renal Cell Cancer Cells by Inducing Autophagy Via AMPK/mTOR Signaling Pathway.

Inhibition of Human Hepatocellular Carcinoma Tumor Angiogenesis by Sirna Silencing of VEGF Via Hepatic Artery Perfusion.

In Vitro and In Vivo Preventive Effects of Thymoquinone against Breast Cancer: Role of DNMT1

Thymoquinone protects thioacetamide‐induced chronic liver injury by inhibiting TGF‐β1/Smad3 axis in rats

Thymoquinone Inhibits Metastatic Phenotype and Epithelial‑mesenchymal Transition in Renal Cell Carcinoma by Regulating the LKB1/AMPK Signaling Pathway.

Thymoquinone Inhibits Angiotensin II-Induced Proliferation and Migration of Vascular Smooth Muscle Cells Through the AMPK/PPARγ/PGC-1α Pathway.

Thymoquinone Attenuates Liver Fibrosis Via PI3K and TLR4 Signaling Pathways in Activated Hepatic Stellate Cells.

HOXD3 Targeted by Mir-203A Suppresses Cell Metastasis and Angiogenesis Through VEGFR in Human Hepatocellular Carcinoma Cells

MicroRNA-22-3p and MicroRNA-149-5p Inhibit Human Hepatocellular Carcinoma Cell Growth and Metastasis Properties by Regulating Methylenetetrahydrofolate Reductase

Thymoquinone Inhibits Bone Metastasis of Breast Cancer Cells Through Abrogation of the CXCR4 Signaling Axis

Inhibition of induced-hepatic cancer in vivo through IQGAP1-shRNA gene therapy and modulation of TRAIL-induced apoptosis pathway

Upregulation of SIRT1-AMPK by Thymoquinone in Hepatic Stellate Cells Ameliorates Liver Injury.

Thymoquinone Inhibits the Proliferation and Invasion of Esophageal Cancer Cells by Disrupting Theakt/gsk-3/Wnt Signaling Pathway Viaptenupregulation

Thymoquinone Alleviates Thioacetamide-Induced Hepatic Fibrosis and Inflammation by Activating Lkb1-Ampk Signaling Pathway in Mice

The antitumor effect of TIG3 in liver cancer cells is involved in ERK1/2 inhibition